Logo image of ELUT

ELUTIA INC (ELUT) Stock Fundamental Analysis

USA - NASDAQ:ELUT - US05479K1060 - Common Stock

0.88 USD
-0.02 (-1.93%)
Last: 10/3/2025, 8:00:02 PM
0.8976 USD
+0.02 (+2%)
After Hours: 10/3/2025, 8:00:02 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ELUT. ELUT was compared to 536 industry peers in the Biotechnology industry. ELUT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ELUT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ELUT has reported negative net income.
In the past year ELUT has reported a negative cash flow from operations.
In the past 5 years ELUT always reported negative net income.
In the past 5 years ELUT always reported negative operating cash flow.
ELUT Yearly Net Income VS EBIT VS OCF VS FCFELUT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -63.63%, ELUT perfoms like the industry average, outperforming 40.86% of the companies in the same industry.
Industry RankSector Rank
ROA -63.63%
ROE N/A
ROIC N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELUT Yearly ROA, ROE, ROICELUT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K -3K -4K

1.3 Margins

ELUT has a Gross Margin of 44.67%. This is in the better half of the industry: ELUT outperforms 75.00% of its industry peers.
In the last couple of years the Gross Margin of ELUT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ELUT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
ELUT Yearly Profit, Operating, Gross MarginsELUT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

0

2. Health

2.1 Basic Checks

ELUT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ELUT has been increased compared to 1 year ago.
The number of shares outstanding for ELUT has been increased compared to 5 years ago.
ELUT has a worse debt/assets ratio than last year.
ELUT Yearly Shares OutstandingELUT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ELUT Yearly Total Debt VS Total AssetsELUT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ELUT has an Altman-Z score of -11.81. This is a bad value and indicates that ELUT is not financially healthy and even has some risk of bankruptcy.
ELUT's Altman-Z score of -11.81 is on the low side compared to the rest of the industry. ELUT is outperformed by 76.31% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.81
ROIC/WACCN/A
WACC14.76%
ELUT Yearly LT Debt VS Equity VS FCFELUT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 0.59 indicates that ELUT may have some problems paying its short term obligations.
ELUT's Current ratio of 0.59 is on the low side compared to the rest of the industry. ELUT is outperformed by 92.35% of its industry peers.
A Quick Ratio of 0.45 indicates that ELUT may have some problems paying its short term obligations.
With a Quick ratio value of 0.45, ELUT is not doing good in the industry: 93.10% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.45
ELUT Yearly Current Assets VS Current LiabilitesELUT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.72% over the past year.
ELUT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.25%.
Measured over the past years, ELUT shows a very negative growth in Revenue. The Revenue has been decreasing by -10.69% on average per year.
EPS 1Y (TTM)67.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.65%
Revenue 1Y (TTM)-25.25%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-0.45%

3.2 Future

ELUT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.94% yearly.
The Revenue is expected to grow by 53.16% on average over the next years. This is a very strong growth
EPS Next Y75.22%
EPS Next 2Y35.46%
EPS Next 3Y26.94%
EPS Next 5YN/A
Revenue Next Year15.32%
Revenue Next 2Y40.13%
Revenue Next 3Y53.16%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ELUT Yearly Revenue VS EstimatesELUT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
ELUT Yearly EPS VS EstimatesELUT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELUT. In the last year negative earnings were reported.
Also next year ELUT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELUT Price Earnings VS Forward Price EarningsELUT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELUT Per share dataELUT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ELUT's earnings are expected to grow with 26.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.46%
EPS Next 3Y26.94%

More info and screens

0

5. Dividend

5.1 Amount

ELUT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELUTIA INC

NASDAQ:ELUT (10/3/2025, 8:00:02 PM)

After market: 0.8976 +0.02 (+2%)

0.88

-0.02 (-1.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners39.78%
Inst Owner ChangeN/A
Ins Owners2.36%
Ins Owner Change4.16%
Market Cap37.31M
Analysts82.5
Price Target5.61 (537.5%)
Short Float %0.13%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.77%
Min EPS beat(2)-32.64%
Max EPS beat(2)52.18%
EPS beat(4)2
Avg EPS beat(4)11.01%
Min EPS beat(4)-32.64%
Max EPS beat(4)52.18%
EPS beat(8)2
Avg EPS beat(8)-38.99%
EPS beat(12)4
Avg EPS beat(12)-31.86%
EPS beat(16)5
Avg EPS beat(16)-27.71%
Revenue beat(2)0
Avg Revenue beat(2)-8.68%
Min Revenue beat(2)-11.1%
Max Revenue beat(2)-6.26%
Revenue beat(4)0
Avg Revenue beat(4)-9.63%
Min Revenue beat(4)-12.03%
Max Revenue beat(4)-6.26%
Revenue beat(8)2
Avg Revenue beat(8)-4.06%
Revenue beat(12)2
Avg Revenue beat(12)-5.1%
Revenue beat(16)4
Avg Revenue beat(16)-3.45%
PT rev (1m)-15.38%
PT rev (3m)-26.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.29%
EPS NY rev (1m)0%
EPS NY rev (3m)6.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.58
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0.56
BVpS-0.99
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.63%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.67%
FCFM N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
F-Score2
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.64%
Cap/Sales 4.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.45
Altman-Z -11.81
F-Score2
WACC14.76%
ROIC/WACCN/A
Cap/Depr(3y)14.22%
Cap/Depr(5y)13.83%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.65%
EPS Next Y75.22%
EPS Next 2Y35.46%
EPS Next 3Y26.94%
EPS Next 5YN/A
Revenue 1Y (TTM)-25.25%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-0.45%
Revenue Next Year15.32%
Revenue Next 2Y40.13%
Revenue Next 3Y53.16%
Revenue Next 5YN/A
EBIT growth 1Y21.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.81%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-79.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79%
OCF growth 3YN/A
OCF growth 5YN/A